Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States-Reference-Cited by-同舟云学术

Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States

Published:2023-07-04 Issue:9 Volume:98 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Potnis Kunal C.¹^ORCID,Viswanathan Giri²,Bona Robert D.³,Ito Satoko³,Kempton Christine L.⁴,Pandya Ankur⁵,Krumholz Harlan M.⁶⁷^ORCID,Goshua George³^ORCID

Affiliation:

1. Department of Internal Medicine Yale School of Medicine New Haven Connecticut USA

2. Yale College New Haven Connecticut USA

3. Section of Hematology, Department of Internal Medicine Yale School of Medicine and Yale Cancer Center New Haven Connecticut USA

4. Department of Hematology and Medical Oncology and Hemophilia of Georgia Center for Bleeding and Clotting Disorders of Emory Emory University School of Medicine Atlanta Georgia USA

5. Department of Health Policy and Management Harvard T.H. Chan School of Public Health Boston Massachusetts USA

6. Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine New Haven Connecticut USA

7. Center for Outcomes Research and Evaluation Yale New Haven Hospital New Haven Connecticut USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27014

Reference12 articles.

1. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

2. Emicizumab for the treatment of haemophilia a: a narrative review;Franchini M;Blood Transfus,2019

3. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study

4. Centers for Medicare & Medicaid Services.ASP Drug Pricing Files.2022.

5. WFH Guidelines for the Management of Hemophilia, 3rd edition

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab as a Promising Form of Therapy for Type A Hemophilia - AReview of Current Knowledge from Clinical Trials;Current Protein & Peptide Science;2024-11